ClinicalTrials.gg
Not yet recruitingNCT07873671Updated Oct 14, 2026

A Trial of RLX-2508-102 in Healthy Volunteers

An Early Phase 1 interventional study of RLX-2508 and RLX-2508 in Influenza, sponsored by Atridia Pty Ltd.. Not yet recruiting at 3 sites in Australia. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Early Phase 1, Interventional, and Prevention

How we know

Updated Oct 14, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 99 studies in Influenza, Human with a site in Australia — 8 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · Australia.

Planned enrollment
70th of 87
101 · median 360
Started
2026
with 3 others
Phase 1
20 of 99
3 open now
Primary completion
2029-01
later than 11 of 11 live
Registered
99th of 99
by date

Among the 99 studies in Influenza, Human with a site in Australia, this one is the 70th largest by planned enrollment of the 87 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 11 of the 11 other live ones, and was the 99th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

8 of the 99 studies in Influenza, Human with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Influenza, Human with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main inclusion criteria

  1. Male or female participant, including general adult populations, and participants of Japanese heritage.
  2. Capable to give consent and have ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written , be able to comply with all the requirements, and able to complete the study.
  3. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, (BMI) between 19.0 and 32.0 kg/m2 (inclusive) at screening and baseline, except for Japanese participants, for whom a BMI range of 18.0 to 28.0 kg/m² (inclusive) will apply.
  4. Men and must agree to take highly effective methods

Main exclusion Criteria

  1. History or evidence of disorders.
  2. Individuals with a history of drug allergies, specific allergies, or known history or suspected of being allergic to the study drug or same class drug or any component of it.
  3. Previous participation in another clinical trial (including medical devices or another drug) within 3 months or 5 half-lives, whichever is longer prior to screening.
  4. History of excessive smoking in the past 1 month prior to screening
  5. History of illicit or prescription drug abuse or addiction within 1 year of screening, or positive urine drug screen at baseline.
  6. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
101 participants (estimated)

Study arms

  • Experimental
    Dose level 1 in healthy adultsCohort

    Single dose of RLX-2508 /placebo given subcutaneously

    Drug: RLX-2508

  • Experimental
    Cohort 2 -Dose level 2 in healthy adults

    Drug: RLX-2508

  • Experimental
    Cohort 3- Dose level 3 in healthy adults

    Repeated doses of RLX-2508 /placebo given subcutaneously

    Drug: RLX-2508

  • Experimental
    Cohort 4: Dose level 3 in healthy volunteers of Japanese heritage

    Single dose of RLX-2508 /placebo given subcutaneously

    Drug: RLX-2508

Interventions

  • DrugRLX-2508

    Single dose RLX-2508 /placebo given subcutaneously - Dose level 1

  • DrugRLX-2508

    Single dose RLX-2508 /placebo given subcutaneously - Dose level 2

  • DrugRLX-2508

    Repeated dose of RLX-2508 /placebo given subcutaneously - Dose level 3

  • DrugRLX-2508

    Single dose of RLX-2508 /placebo given subcutaneously - Dose level 3

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events

    Number of participants with Adverse events and Serious adverse events

    Time frame: Day 360 & Day 450

Secondary outcomes

  1. PK Profile of RLX-2508 After a Single and multiple-Dose Administration • Pharmacokinetics - Cmax

    Maximum observed plasma concentration (Cmax)

    Time frame: Day 360 & Day 450

  2. PK Profile of RLX-2508 After a Single and multiple-Dose Administration • Pharmacokinetics - AUC0-inf

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: Day 360 & Day 450

  3. PK Profile of RLX-2508 After a Single and multiple-Dose Administration • Pharmacokinetics - AUC0-inf

    Time to reach maximum observed plasma concentration (Tmax)

    Time frame: Day 360 & Day 450

  4. PK Profile of RLX-2508 After a Single and multiple-Dose Administration • Pharmacokinetics - t1/2

    Terminal elimination half-life (t1/2)

    Time frame: Day 360 & Day 450

  5. Immunogenicity profile of RLX-2508 after a Single and multiple dose administration:

    incidence of anti-drug antibodies (ADAs)

    Time frame: Day 360 & Day 450

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 26 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 14, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Jan 30, 2029
CompletionEst.
Jan 30, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07873671
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Oct 14, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Jan 30, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Kathy You
Contact
kathyyou@atridia.com
+61 02 9299 0433
Eimy Minowa
Contact
eimy.minowa@atridia.com
61 432223162

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion